

Massy, 25 February 2015

## Quantum Genomics reports total capital increase after stabilization period: €12.9 million

- 🔴 Overallotment option fully exercised: additional €1.7 million raised through the issue of 267,375 new shares at €6.30
- 🔴 Market capitalization: €52.8 million

**Quantum Genomics (Alternext - FR0011648971 - ALQGC)**, a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces that broking firm Invest Securities, as Lead Manager and Bookrunner, has informed the Company that the overallotment option, granted to it as part of the capital increase with public offering on the Euronext Alternext market in Paris, was exercised in full in the amount of an additional €1.7 million corresponding to the issue of 267,375 additional shares at the offer price of €6.30 per share.

The final amount of the capital increase is therefore €12,9 million, corresponding to the issue of 2,049,875 new shares.

As a result of these transactions, Quantum Genomics' share capital consists of 6,859,962 shares, for a market capitalization of €52.8 million based on its closing share price on 23 February 2015 (€7.70).

**Lionel Ségard, Chairman & CEO of Quantum Genomics, says:**

*"The exercise in full of the overallotment option confirms the great success of our capital increase, aimed primarily at financing Phase IIa of our antihypertensive molecule QGC001. The funds raised, exceeding our expectations, reinforces our confidence and puts us in a strong position, not least in our discussions with our future pharmaceutical laboratory partners."*

In compliance with Article 631-10 of the General Regulations of the *Autorité des Marchés Financiers*, Invest Securities, as underwriter, reports that stabilization:

- began on 13 February 2015 on Quantum Genomics (ISIN code: FR0011648971 – Ticker: ALQGC);
- was completed on 23 February 2015;
- required no transactions on the stock market.

## CONTACTS

### Quantum Genomics

Lionel Ségard  
Chairman & Chief Executive Officer  
01 60 13 76 80

### Quantum Genomics

Marc Karako  
Vice-President Finance – Investor  
Relations  
01 60 13 76 84  
[marc.karako@quantum-genomics.com](mailto:marc.karako@quantum-genomics.com)

### ACTUS

Jean-Michel Marmillon  
Press Relations  
01 53 67 36 73  
[jmmarmillon@actus.fr](mailto:jmmarmillon@actus.fr)

## ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company whose mission is to develop new therapies for unsatisfied medical needs in the field of cardiovascular diseases, in particular high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on the inhibition of Aminopeptidase A in the brain (BAPAI - Brain Aminopeptidase A Inhibition), the result of more than 20 years' academic research in laboratories at Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).

## Financial intermediaries

Invest *Securities*  
Corporate Finance

**Advisor**

Invest *Securities*  
Société de Bourse

**Lead Manager and  
Bookrunner**

  
**ACTUS**  
finance & communication

**Financial communication**

## Disclaimer

Copies of the Prospectus approved by the French Financial Markets Authority (AMF) on 26 January 2015 under number I.15-036 are available on the Company's website ([www.quantum-genomics.com](http://www.quantum-genomics.com) or [www.QGC-BOURSE.COM](http://www.QGC-BOURSE.COM)) and on the AMF website ([www.amf-france.org](http://www.amf-france.org)) or can be obtained free of charge on request from the Company's registered office, 2 -12 Chemin des Femmes, Bâtiment l'Odyssée, 91300 Massy, France.

**The public is invited to read the risks described in Chapter IV "Risk factors" and in Part II, chapter II "Risk factors related to the offering" in the Prospectus.**

This communication and the information in it do not constitute an offer to buy or subscribe, or an encouragement to buy or subscribe, to shares in Quantum Genomics (the "Shares") in any country.

This communication does not constitute and may not be regarded as constituting an offer to the public, an offer to buy, or offer to invest, or intended to solicit public interest with a view to a public offering.

This communication is promotional in nature and does not constitute a prospectus in the sense of Directive 2003/71/EC of the European Parliament and Council of 4 November 2003, as amended, in particular by Directive 2010/73/EU of the European Parliament and Council of 24 November 2010, as amended and as transposed in each Member State of the European Economic Area (the "Prospectus Directive").

With respect to the Member States of the European Economic Area other than France and Belgium (the "Member States") that transposed the Prospectus Directive, no action was taken or will be taken to permit a public offering of shares that would require the publication of a prospectus in any of the Member States. Consequently, the Shares may be offered in the Member States only to (a) legal entities who are qualified investors as defined in the

Prospectus Directive or (b) in other cases not requiring Quantum Genomics to publish a prospectus under Article 3(2) of the Prospectus Directive.

This communication is not being distributed, or its distribution approved, by an authorized person ("authorized person") in the sense of Article 21(1) of the Financial Services and Markets Act 2000. Consequently, this communication is addressed to and intended only for (i) persons outside the United Kingdom, (ii) investment professionals in the sense of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, (iii) persons referred to in Article 49(2) (a) to (d) (large-cap companies, unregistered associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, or (iv) any other person to whom this communication may legally be addressed (the persons mentioned in paragraphs (i), (ii), (iii) and (iv) being together designated as "Qualified Persons"). The shares are intended only for Qualified Persons and any invitation, offer or agreement relating to the subscription, purchase or acquisition of shares may be addressed to or concluded with Qualified Persons only. Any person other than a Qualified Person must refrain from using or relying on this communication and the information in it. This communication does not constitute a prospectus approved by the Financial Services Authority or by any other regulating authority in the United Kingdom in the sense of Section 85 of the Financial Services and Markets Act 2000.

This communication does not constitute an offer of tradable securities or any solicitation to purchase or invest in tradable securities in the United States of America. The securities that are the subject of this communication have not been and will not be registered in the sense of the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States without registration or exemption from the registration obligation pursuant to the U.S. Securities Act. The Shares have not been and will not be registered under the U.S. 1933 Securities Act and Quantum Genomics has no intention of proceeding with any public offering of its shares in the United States.

The distribution of this communication in certain countries may violate applicable laws. Persons in possession of this communication must inform themselves of any potential local restrictions and comply with them.

The prospectus approved by the French Financial Markets Authority contains forward looking statements. No guarantee can be given that such forward looking statements will be borne out by actual events as they are subject to risks such as those described in the Company's prospectus, and to changes in economic conditions, financial markets and the markets in which Quantum Genomics operates.

Invest Securities, as underwriter, may, but is under no obligation to and may at any time terminate, for a period of 30 days counting from the date that the offer price is set, which according to the indicative timeline is 28 January to 28 February 2015, trade for the purpose of stabilizing the market in Quantum Genomics shares, in compliance with applicable laws and regulations and in particular Regulation (EC) 2273/2003 of the Commission of 22 December 2003. Trades conducted for these purposes are intended to support the market price of Quantum Genomics shares and may affect the share price.